Abstract
Twenty-four evaluable patients with advanced or recurrent epithelial ovarian carcinoma who progressed on platinum-containing combination chemotherapy were treated with medroxyprogesterone acetate (C.T. Provera) 50 mg orally three times a day until progression of disease. One patient had a partial response (4.2%), 9 patients had stable disease (37.5%), and 14 (58.3%) had increasing disease. The 95% upper confidence limit for response is less than or equal to 18.3%. There was no toxicity associated with its use. C.T. Provera has limited activity in patients with epithelial ovarian cancer who have failed combination chemotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 149-151 |
| Number of pages | 3 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 16 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 1 1993 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers'. Together they form a unique fingerprint.
Cite this
Malfetano, J., Beecham, J. B., Bundy, B. N., & Hatch, K. D. (1993). A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers. American Journal of Clinical Oncology: Cancer Clinical Trials, 16(2), 149-151. https://doi.org/10.1097/00000421-199304000-00014